 Enveric Biosciences NASDAQ: ENVB announced data from a preclinical rodent model evaluating EV102, the companys cannabidiol CBD based product in development for the topical treatment of radiodermatitis. Radiodermatitis, the most common side effect of radiation therapy, is a physical skin irritation with symptoms ranging from red rash to open wounds. 